Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Madrigal Pharmaceuticals (MDGL) shares jumped after Novo Nordisk (NVO) announced that a trial showed its weight-loss drug ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

Madrigal Pharmaceuticals continues to focus on addressing the unmet medical needs in NASH/MASH treatment and aims to enhance patient outcomes with its pioneering therapies. The company anticipates ...

Investors with a lot of money to spend have taken a bullish stance on Madrigal Pharmaceuticals MDGL. And retail traders should know. We noticed this today when the positions showed up on publicly ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) saw unusually-high trading volume on Friday following a better than expected earnings announcement.Approximately 560,141 shares ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...